Research · PMID 37911485 · Landmark study
Review date on record: Aug 2026. Named clinician approval is not independently verified on this page.
Domestic Correspondence.
International dental journal (Philadelphia, Pa.) · March 1890
What this study found
This study examines Domestic Correspondence. Editorial review is required before publishing clinical takeaways.
Why this trial matters
SELECT semaglutide obesity CVOT
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Supporting literature
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open evidence analysis